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Abstract
Background: Guidelines recommend foot orthoses for people with both early (< 2 years) and established
rheumatoid arthritis (RA). While prefabricated foot orthoses are cheaper and can exhibit comparable effects to
customised devices, the available evidence for their effectiveness is inconsistent. Little is known about what types
of foot orthoses clinicians prescribe. This study describes the foot orthoses prescription habits of podiatrists for
people with rheumatoid arthritis.
Methods: One hundred and eighty-three podiatrists from the United Kingdom (UK) (n = 88), Australia (n = 68) and
New Zealand (n = 27) completed a self-administered, online survey regarding the types of foot orthoses prescribed
in clinical practice for people with RA. This study forms part of a wider international survey exploring foot orthosis
prescription habits.
Results: UK respondents were more likely to prescribe prefabricated orthoses for early RA (n = 47, 53%) and
customised orthoses for established RA (n = 47, 53%). Respondents in Australia were more likely to prescribe
customised orthoses for both early (n = 32, 47%) and established (n = 46, 68%) RA, whilst respondents in New Zealand
were more likely to prescribe prefabricated orthoses for both early (n = 16, 59%) and established (n = 10, 37%) disease.
Irrespective of disease stage, the use of foam impression boxes was more prevalent in the UK and New Zealand when
capturing a model of the feet prior to manufacturing customised orthoses. In contrast, electronic scanning and plaster
of Paris were more common in Australia. Computer aided manufacture was utilised more frequently among
respondents in Australia than in the UK and New Zealand. Respondents in all three countries specified more flexible
shell materials for established RA, compared to early disease. Cushioning top covers (e.g. PORON® or polyurethane)
were most frequently specified in all countries for both disease stages.
Conclusions: Considerable variation was seen in the self-reported foot orthoses prescription habits of respondents for
people with RA. Variation between countries and disease stage was seen in type of orthoses, specific brands,
manufacturing methods, and materials prescribed. The results allow podiatrists and broader health service providers to
compare their practice against reported national and international patterns.
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Background
Foot orthoses (FOs) are frequently prescribed in clinical
practice as an intervention for people with rheumatoid
arthritis (RA), a chronic inflammatory disease with an
estimated global prevalence of up to 1% [1]. The condi-
tion has significant economic impact. In 2009, RA
accounted for over $355 million of Australian health
expenditure [2], whilst a 2010 report estimated that
the overall cost of productivity losses to the United
Kingdom (UK) economy due to RA was almost £8
billion per year [3].
Foot pain is a prevalent and debilitating symptom of
RA throughout the disease course, in both early (< 2 years)
and established disease [4]. Foot pain frequently persists
even when clinical remission of disease activity is achieved
[5]. Studies consistently suggest that around 90% of people
with RA experience foot problems during the course of
their disease [4, 6]. Mechanical factors play a key role in
the progression of foot deformity, and are increasingly
thought to have a major role in the persistence of foot
pathology [7–9]. Mechanical therapies, such as foot
orthoses (FOs), offload painful joints and periarticular
structures and are used to reduce pain, disability, and
improve quality of life in people with RA [10, 11]. The
foot is more amenable to treatment early in the disease
course, prior to the development of irreversible joint
damage and deformity [12, 13]. Earlier intervention with
FOs has been linked to greater improvements in
self-reported foot pain and disability [12]. As such, FOs
are now widely recommended in key guidelines in the UK
and Australia [14, 15].
FOs vary broadly in terms of their design, ranging
from simple cushioning FOs to functional FOs, and their
manufacturing methods, from generic mass produced
prefabricated FOs to individual customised devices [16].
This variation is further confounded by additions such
as posting, wedges and pads. Prefabricated FOs also vary
considerably in terms of their physical form and material
composition, which in turn affect their mechanical
properties [17, 18].
Although systematic reviews have highlighted the need
for more studies to determine the clinical and cost
effectiveness of specific FOs in RA [19, 20], there are a
number of small randomised controlled trials reported
in the literature. Customised rigid and semi rigid FOs
have been shown to reduce foot pain among people with
RA who have metatarsalgia [21] and early rearfoot
valgus [11]. However, the manufacture of custom FOs is
complex and is frequently conducted by offsite commer-
cial manufacturers often over a period of several weeks,
which inherently delays the initiation of therapy, poten-
tially reducing clinical benefit. Prefabricated FOs are, by
definition, pre-made and can therefore be supplied
immediately, eliminating the need to wait for off-site
manufacture and enabling initiation of therapy as soon
as the first clinical contact.
Some prefabricated FOs can exhibit comparable mech-
anical effects to more expensive custom devices [22, 23]
and as such, prefabricated FOs may represent a substan-
tial potential saving for health services [24]. Despite the
frequency of foot complaints in RA and the financial
burden of the condition on the economy, there is limited
data relating to cost-effectiveness of FOs for people with
RA [11, 25]. A recent exploratory study suggested that
semi rigid customised FOs can improve pain and disabil-
ity in people with established RA, compared to simple
insoles. However, the customised FOs were more expen-
sive to manufacture, with no significant cost per
quality-adjusted life year gain [26]. An abundance of FO
brands and sub-types are available on the market, but
little is known about what types of FO are prescribed for
people with RA, despite renewed interest in FO pre-
scription patterns [27–30]. The only study to date to
explore FO prescription habits for people with this
condition was conducted over a decade ago [31]. The
author reported that the majority of podiatrists surveyed
prescribed non-rigid EVA FOs for people with early RA
and simple accommodative FOs for people with estab-
lished disease.
The aim of this study was to describe current FO pre-
scription habits of podiatrists from the UK, Australia
and New Zealand for people with RA.
Methods
As part of a wider international survey of FO prescrip-
tion habits among podiatrists, this descriptive study uti-
lised a cross-sectional, online, self-administered survey
to elicit FO prescription habits among registered podia-
trists for people with RA. Ethical approval was received
from the School of Medicine Research Ethics Commit-
tee, University of Leeds (Ref: MREC15–052). Subsequent
approval was also gained from La Trobe University (Ref:
MREC15–052) and Auckland University of Technology
(Ref: 16/133). Participant consent was implied by com-
pletion of the survey and it was accessible from June
2016 to November 2016.
Survey design
An electronic survey technique was used, utilising the
Bristol Online Survey platform (http://onlinesurveys.a-
c.uk) to enable international completion. Further details
of how the survey questions were developed and piloted
are published elsewhere [30]. The survey (Additional file
1) contained a subsection designed to elicit FO prescrip-
tion habits for people with early and established RA. In
relation to each stage of the condition, respondents were
asked to identify the type of FO most frequently
prescribed, prefabricated FO brands provided, and the
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methods used to capture the 3D shape of the foot,
manufacturing techniques, shell, rearfoot posting and
top cover materials most frequently specified when
prescribing customised FOs.
Participants and data collection
Participants were invited to complete an anonymous on-
line survey via professional e-newsletters, special interest
groups, discussion forums, and professional publications,
across the UK, Australia and New Zealand. Data from
respondents practising in any other countries who
participated in the survey were excluded from the main
analysis due to potential differences in education and
scope of practice, but were presented as supplementary
data. The survey was also promoted at local and regional
meetings during the study period. To be eligible to
complete the survey, participants had to be registered
podiatrists, able to access the survey online, and able to
understand written English.
Terminology
Within the survey, early RA referred to disease duration
of 2 years or less, whilst established RA referred to those
who had the condition for more than 2 years. In the
absence of universally agreed definitions of FO types,
FOs were described in three categories. Simple FOs were
defined as flat insoles with or without padding to accom-
modate painful areas or lesions. Prefabricated FOs were
considered as devices made to a generic foot shape, con-
toured for the arch, and included modular prefabricated
orthoses that can be altered by clinicians (e.g. by the
addition of posting, wedges, pads or top covers). Custo-
mised FOs were considered as devices manufactured for
a specific person based on a 3D impression or compu-
terised image of that person’s foot, and produced using
computer aided device/manufacturing (CAD/CAM) or
more traditional manufacturing techniques (e.g. foam
impression box or plaster of Paris cast).
Analysis
Survey data was entered into SPSS v 21 (Armonk, NY:
IBM Corp) and analysed using descriptive statistics. Free
text responses relating to prefabricated FOs prescribed
were considered to be valid if they contained the name
of a prefabricated FO brand. Invalid responses were
excluded.
Results
Demographics
Two hundred and sixty-four (264) podiatrists completed
the survey. The majority of respondents practised in the
United Kingdom (47%, n = 124), Australia (30%, n = 79)
and New Zealand (12%, n = 32).
Eighty-eight (71%) respondents in the UK indicated
that they prescribed FOs for people with RA. The major-
ity (n = 87, 99%) gained their primary podiatry qualifica-
tion in the UK. Fifty-two (59%) UK respondents were
female. UK respondents qualified between 1973 and
2016, with a mean (SD) of 19.7 (11.6) years since qualifi-
cation. Thirty (34%) worked solely in the public sector,
29 (33%) worked solely in private practice, and 29 (33%)
worked across both sectors. Comparisons between the
public and private sectors were not made among re-
spondents in Australia or New Zealand due to the
limited number of respondents working solely in the
public sector.
Sixty-eight (86%) respondents in Australia prescribed
FOs for people with RA, 59 (87%) of whom qualified
there. Thirty-four (50%) Australian respondents were
female. Respondents in Australia qualified between 1968
and 2016, with a mean (SD) of 17.1 (11.5) years since
qualification. Two (3%) Australian respondents worked
solely in the public sector, 55 (81%) worked solely in pri-
vate practice, and 11 (16%) worked across both sectors.
Twenty-seven (84%) respondents in New Zealand
prescribed FOs for people with RA, 22 (82%) of whom
qualified there. Eighteen (67%) New Zealand respon-
dents were female. Respondents practising in New Zea-
land qualified between 1979 and 2016, with a mean (SD)
of 15.14 (11.56) years since qualification. Two (7%) New
Zealand respondents worked solely in the public sector,
10 (37%) worked solely in private practice, and 15 (56%)
worked across both sectors.
Twenty-two (76%) respondents practising in other
countries prescribed FOs for people with RA (Additional
file 2).
Types of FOs prescribed
Figure 1 shows the types of FOs respondents were most
likely to prescribe for early and established RA. The
majority of respondents in the UK and New Zealand re-
ported they were more likely to prescribe prefabricated
FOs than other FO types for early RA. Respondents in
Australia reported they were more likely to prescribe
customised FOs than other FO types for early RA, but
were almost twice as likely to prescribe prefabricated
FOs for early RA than for established RA.
The majority of respondents in the UK and Australia
reported they were more likely to prescribe customised
FOs than other FO types for established RA. The pre-
scription pattern among UK respondents was consistent
regardless of whether they worked solely in the public
sector or solely in private practice (Fig. 2). Respondents
in New Zealand reported they were more likely to
prescribe prefabricated FOs than other types of FO for
established RA, but were twice as likely to prescribe
customised FOs for established RA than for early RA.
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Fig. 1 FO type most likely to be prescribed for early and established RA
Fig. 2 FO type prescribed for early and established RA among podiatrists in the UK by working sector
Chapman et al. Journal of Foot and Ankle Research            (2019) 12:7 Page 4 of 12
Prefabricated FOs
Figure 3 illustrates the variety of prefabricated FO
brands prescribed by respondents in clinical practice for
early and established RA. Fifty-four (61%) UK respon-
dents who prescribed FOs for RA in practice provided a
valid response when asked which prefabricated FO was
most frequently used for people with early RA. Of these,
47 (87%) indicated a single preferred brand, six (11%) in-
dicated two preferred brands, and one (2%) respondent
indicated three preferred brands. Sixteen different pre-
fabricated FO brands were used among respondents for
early RA. Slimflex® FOs were over twice as likely to be
prescribed as other brands. However, when considering
respondents working solely in private practice, Vasyli®
and TalarMade™ were more frequently used (Table 1).
Forty (59%) respondents in Australia provided a valid
response when asked which prefabricated FO was most
frequently used for people with early RA. Thirty-four
(85%) indicated a single preferred brand, five (12.5%) in-
dicated two preferred brands, and one (2.5%) respondent
indicated three preferred brands. Twelve different
prefabricated FO brands were used among respondents
for early RA. Formthotics™ were over three times more
likely to be prescribed by respondents in Australia for
early RA than other prefabricated FO brands.
Twenty-one (78%) respondents in New Zealand pro-
vided a valid response when asked which prefabricated
FO was most frequently used for people with early RA.
Nineteen (90%) indicated a single preferred brand, whilst
two (10%) respondents indicated two preferred brands.
Seven different prefabricated FO brands were used
among respondents for early RA. Footbionics® was the
most frequently specified brand.
Twenty-eight (32%) UK respondents provided a valid
response when asked which prefabricated FO they
most frequently used for people with established RA.
Fig. 3 Most frequently prescribed prefabricated FO brands for early and established RA
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Twenty-three (82%) stated one preferred prefabricated
FO brand, four (14%) stated two brands, and one
(4%) respondent stated five brands. Twelve different
prefabricated FO brands were used among UK re-
spondents for established RA. Overall, X-Line® was
the most frequently prescribed brand, followed by
Slimflex® and Vasyli®. However, none of the UK re-
spondents working solely in private practice indicated
Slimflex® or X-Line® as a preferred brand (Table 2).
Thirty-eight (56%) Australian respondents provided
a valid response when asked which prefabricated FO
they most frequently used for people with established
RA. Thirty-five (92%) indicated a single preferred
brand, two (5%) indicated two preferred brands, and
one (3%) respondent indicated three preferred brands.
Ten different prefabricated FO brands were used
among respondents in Australia for established RA.
Formthotics™ were over four times more likely to be
prescribed than other prefabricated FO brands.
Thirteen (48%) respondents in New Zealand gave a
valid response when asked which prefabricated FO
they most frequently used for people with established
RA. Eleven (85%) indicated one preferred prefabri-
cated FO brand, and two (15%) respondents indicated
two preferred brands. Four different prefabricated FO
brands were used among respondents in New Zealand
for established RA; Formthotics™ was the most fre-
quently specified brand.
Table 1 Most frequently used prefabricated FO brands for early RA by sector
Brand Solely public sector Solely private practice Combination of sectors Total
Express 1 0 0 1
Frelen 0 1 0 1
ICB 1 0 0 1
Interpod 3 1 1 5
Kent NHS 0 1 1 2
LBG Bio 4 1 2 7
LBG Langer 0 3 1 4
Scholl 1 0 0 1
Salford Insole™ 1 0 1 2
RX® 0 0 1 1
Shortez 1 0 0 1
Sidas 0 2 0 2
Slimflex® 10 1 5 16
TalarMade™ 2 3 2 7
Vasyli® 0 4 0 4
X-Line® 4 0 3 7
Table 2 Most frequently used prefabricated FO brands for established RA by sector
Brand Solely public sector Solely private practice Combination of sectors Total
Diaped 0 0 1 1
Interpod 1 0 1 2
Kent NHS 0 0 1 1
LBG Bio 1 1 0 2
LBG Langer 0 1 2 3
Rightstride® 1 0 0 1
RX® 0 0 1 1
Sidas 0 2 0 2
Slimflex® 4 0 2 6
TalarMade™ 1 0 3 4
Vasyli® 0 4 2 6
X-Line® 4 0 3 7
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Customised FO provision
Forty-seven (53%) respondents in the UK indicated that
they prescribed customised FOs for people with early
RA at least some of the time, compared to 48 (71%) re-
spondents in Australia and 16 (59%) in New Zealand.
For established RA, 63 (72%) UK respondents indicated
that they prescribed customised FOs at least some of the
time, compared to 59 (87%) respondents in Australia
and 18 (67%) in New Zealand.
Manufacturing methods
Table 3 illustrates the range of manufacturing methods
and materials specified when prescribing customised
FOs for early and established RA. Use of foam impression
boxes was most frequently reported among respondents
in the UK to capture the 3D shape of the foot in both
disease stages, regardless of working sector (Table 4).
Respondents in New Zealand also reported using foam
impression boxes most frequently for both stages of RA.
In contrast, respondents in Australia reported using foam
impression boxes least frequently, with almost equal use
of plaster of Paris and electronic scanning. Comparisons
between the public sector and private practice were not
made among respondents in Australia or New Zealand
due to the limited number of respondents working solely
in the public sector.
Respondents in the UK and New Zealand reported
they were slightly more likely to use non-weightbearing
methods to capture the 3D shape of the foot in early
RA, and weightbearing methods in established RA. A
Table 3 Customised FO prescription habits
UK Australia New Zealand
Early RA
(n = 47)
Established RA
(n = 63)
Early RA
(n = 48)
Established RA
(n = 59)
Early RA
(n = 16)
Established RA
(n = 18)
Methods used to capture 3D shape of foot
Plaster of Paris 13 (28%) 17 (27%) 21 (44%) 25 (42%) 5 (31%) 6 (33%)
Foam impression box 28 (59%) 40 (63.5%) 7 (14%) 10 (17%) 9 (56%) 11 (61%)
Electronic scanning/ imaging 6 (13%) 6 (9.5%) 20 (42%) 24 (41%) 2 (13%) 1 (6%)
Weightbearing 21 (45%) 33 (52%) 9 (19%) 16 (27%) 7 (44%) 10 (56%)
Non-weightbearing 26 (55%) 30 (48%) 39 (81%) 43 (73%) 9 (56%) 8 (44%)
Manufacturing techniques
Computer aided manufacture 20 (43%) 30 (48%) 38 (79%) 44 (75%) 8 (50%) 8 (44%)
Traditional manufacturing techniques 27 (57%) 33 (52%) 10 (21%) 15 (25%) 8 (50%) 10 (56%)
Shell material
Highly rigid 6 (13%) 1 (2%) 1 (2%) 1 (2%) 0 (0%) 0 (0%)
Semi rigid 17 (36%) 13 (21%) 20 (42%) 16 (27%) 6 (38%) 3 (17%)
Semi flexible 17 (36%) 28 (44%) 17 (35%) 25 (42%) 9 (56%) 5 (27%)
Highly flexible 7 (5%) 21 (33%) 10 (21%) 17 (29%) 1 (6%) 10 (56%)
Rearfoot posting material
None 6 (13%) 9 (14%) 2 (4%) 4 (7%) 0 (0%) 2 (11%)
Intrinsic 15 (32%) 17 (27%) 12 (25%) 15 (25%) 2 (12.5%) 4 (22%)
Highly rigid 0 (0%) 0 (0%) 1 (2%) 1 (2%) 0 (0%) 0 (0%)
Semi rigid 5 (10%) 3 (5%) 4 (8%) 4 (7%) 1 (6%) 1 (6%)
Semi flexible 21 (45%) 27 (43%) 23 (48%) 27 (46%) 11 (69%) 3 (17%)
Highly flexible 0 (0%) 7 (11%) 6 (13%) 8 (13%) 2 (12.5%) 8 (44%)
Top cover a
Minimal 9 6 3 3 1 0
Cushioning 24 30 26 25 11 11
Cushioning with modification to forefoot 21 41 29 45 7 12
Cushioning with modification to midfoot 11 18 10 18 5 7
Cushioning with modification to rearfoot 8 16 7 14 5 6
a Respondents could select more than one choice for most frequently specified top cover
Chapman et al. Journal of Foot and Ankle Research            (2019) 12:7 Page 7 of 12
large majority of respondents in Australia reported using
non-weightbearing methods for both stages of RA.
UK respondents reported they were slightly more
likely to use traditional manufacturing techniques (e.g.
vacuum forming), as opposed to computer aided manu-
facture, for both stages of RA. Reported use of computer
aided manufacture was higher among respondents work-
ing solely in UK private practice than those working
solely in the public sector (Table 4). Respondents in
New Zealand also reported they were slightly more likely
to use traditional manufacturing techniques for early
RA, although use of traditional and computer aided
manufacture was equal for established RA. Respondents
in Australia reported they were three times more likely
to use computer aided FO manufacture than traditional
manufacture for early RA and over twice as likely for
established RA.
Materials
For early RA, UK respondents most frequently reported
specifying semi flexible (e.g. high density EVA) and semi
rigid (e.g. polypropylene) customised FO shell materials.
Semi rigid shell materials were most frequently specified
for early RA among Australian respondents, whereas
New Zealand respondents most frequently specified
semi flexible materials. Respondents in all three coun-
tries reported most frequently specifying semiflexible
rearfoot posting materials in early RA. For established
RA, semi flexible shell and rearfoot materials were re-
ported to be most frequently specified by UK and Aus-
tralian respondents. Comparatively, New Zealand
respondents reported most frequently specifying highly
flexible (e.g. medium or low density EVA) shell and rear-
foot posting materials. Respondents in the UK and New
Zealand reported most frequently specifying cushioning
Table 4 Customised FO prescription habits by UK sector
Early RA (n = 47) Established RA (n = 63)
Solely public
sector (n = 12)
Solely private
practice (n = 18)
Combination
(n = 17)
Solely public
sector (n = 19)
Solely private
practice (n = 21)
Combination
(n = 23)
Methods used to capture 3D shape of foot
Plaster of Paris 1 (8.3%) 6 (33.3%) 6 (35.3%) 2 (10.5%) 7 (33.3%) 8 (34.8%)
Foam impression box 11 (91.7%) 9 (50%) 8 (47.1%) 17 (89.5%) 11 (52.4%) 12 (52.2%)
Electronic scanning/ imaging 0 (0%) 3 (16.7%) 3 (17.6%) 0 (0%) 3 (14.3%) 3 (13.0%)
Weightbearing 7 (58.3%) 8 (44.4%) 6 (35.3%) 11 (57.9%) 9 (42.9%) 13 (56.5%)
Non-weightbearing 5 (41.7%) 10 (55.6%) 11 (64.7%) 8 (42.1%) 12 (57.1%) 10 (43.5%)
Manufacturing techniques
Computer aided manufacture 3 (25%) 9 (50%) 8 (47.1%) 9 (47.4%) 12 (57.1%) 9 (39.1%)
Traditional manufacturing techniques 9 (75%) 9 (50%) 9 (52.9%) 10 (52.6%) 9 (42.9%) 14 (60.9%)
Shell material
Highly rigid 1 (8.3%) 2 (11.1%) 3 (17.6%) 0 (0.0%) 0 (0.0%) 1 (4.3%)
Semi rigid 4 (33.3%) 5 (27.8%) 8 (47.1%) 2 (10.5%) 7 (33.3%) 4 (17.4%)
Semi flexible 5 (41.7%) 8 (44.4%) 4 (23.5%) 8 (42.1%) 8 (38.1%) 12 (52.2%)
Highly flexible 2 (16.7%) 3 (16.7%) 2 (11.8%) 9 (47.4%) 6 (28.6%) 6 (26.1%)
Rearfoot posting material
None 3 (25%) 2 (11.1%) 1 (5.9%) 3 (15.8%) 3 (14.3%) 3 (13.0%)
Intrinsic 4 (33.3%) 6 (33.3%) 5 (29.4%) 5 (26.3%) 6 (28.6%) 6 (26.1%)
Highly rigid 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Semi rigid 1 (8.3%) 1 (5.6%) 3 (17.6%) 0 (0.0%) 1 (4.8%) 2 (8.7%)
Semi flexible 4 (33.3%) 9 (50%) 8 (47.1%) 10 (52.6%) 9 (42.9%) 8 (34.8%)
Highly flexible 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (5.3%) 2 (9.5%) 4 (17.4%)
Top cover
Minimal 4 3 2 2 3 1
Cushioning 6 10 8 11 9 10
Cushioning with modification to forefoot 6 9 6 12 15 14
Cushioning with modification to midfoot 3 5 3 8 6 4
Cushioning with modification to rearfoot 3 4 1 6 6 4
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(e.g. PORON®) as a top cover for early RA, and cushion-
ing with specific modification or offloading to the fore-
foot for established RA. Cushioning with specific
modification or offloading to the forefoot was the most
reported frequently specified top cover among respon-
dents in Australia for both stages of the condition.
Discussion
This study identified the types of prefabricated FOs used
by respondents in contemporary clinical practice for the
treatment of early and established RA, allowing podia-
trists and broader health service providers to compare
their practice against reported national and international
prescription habits.
Our findings indicate that there is variation across
countries and between sectors in the types of FO pre-
scribed. The majority of respondents in the UK,
Australia and New Zealand reported prescribing FOs for
RA, in line with current guidelines [14]. In the UK, re-
spondents reported they would be more likely to pre-
scribe prefabricated FOs for early RA and customised
FOs for established RA. Respondents in Australia re-
ported they were more likely to prescribe customised
FOs for both stages of the condition, whilst those in
New Zealand reported were more likely to prescribe pre-
fabricated FOs for both stages. These variations in pre-
scription habits between countries may reflect different
health systems and the subsequent health insurance
schemes in place, but further work is required to explore
this fully.
Interestingly, respondents in Australia reported they
were twice as likely to prescribe prefabricated FOs for
early RA compared to established disease, and those in
New Zealand reported they were twice as likely to pre-
scribe customised FOs for established disease compared
to early RA. Reported customised FO shell material
prescriptions also differed according to disease stage.
There is lack of consensus within the podiatry profession
across all three countries [27, 30] regarding which type
of FO should be prescribed for specific conditions, and
the materials to use in FO prescriptions. There is also an
absence of current guidelines to support these decisions.
Our results suggest that respondents may stratify FO
prescriptions for people with RA based on the stage of
the condition, but further work is needed to explore
clinical decision making.
Our results support a previous exploratory survey of
FO prescription habits for people with RA [31], in which
the majority of UK respondents prescribed high or
medium density EVA FOs for early RA. However, our
findings indicate that customised FOs were reported as
most frequently prescribed by UK respondents for
people with established RA, whereas the former survey
found that soft accommodative FOs were prescribed
most often for this stage of the condition. This differ-
ence in prescription habits may reflect the development
of national guidelines in the decade since the previous
survey was conducted, with the provision of functional
FOs now recommended [14].
Our study is the first of its kind to differentiate the
types of prefabricated FOs prescribed in clinical practice
for the treatment of early and established RA. A range
of prefabricated FO brands and models were prescribed
by respondents in practice. Our study found that
Slimflex® and X-Line® brands were most commonly
prescribed in the UK. Comparatively, Formthotics™ was
the most commonly prescribed brand in Australia, and
Formthotics™ and Footbionics® were the most commonly
prescribed brands in New Zealand, despite a current lack
of evidence suggesting that any specific prefabricated FO
is more effective than any other. Nevertheless, this most
likely reflects which prefabricated FOs are most com-
monly used for all foot problems in these countries.
Irrespective of disease stage and working sector, we
found that foam impression boxes were most frequently
used among UK respondents to capture the shape of the
foot when manufacturing customised FOs. Respondents
in New Zealand exhibited similar habits for obtaining an
impression of the feet for customised FO. Although our
results are not directly comparable, these findings are
similar to those from the recent study by Nester et al.,
where 54% of the podiatrists, physiotherapists and or-
thotists surveyed in the UK used foam impression boxes
to capture foot shape, 14% used a scanner, and manual
manufacture and computer aided manufacture were
used in almost equal measure [29]. However, our sample
consisted entirely of podiatrists, therefore results should
not be extrapolated to other professions. Three-dimen-
sional (3D) scanning is considered to be more
reproducible than foam impression boxes and plaster of
Paris in capturing the shape of the foot [32]. However,
barriers to the use of technology in clinical practice,
including usability issues and lack of training, have
previously been identified among UK practitioners pre-
scribing customised FOs within the NHS [33]. Our study
found higher use of electronic scanning among UK re-
spondents working solely in private practice compared
to those working solely in the public sector, with none of
the latter group using this method for either stage of the
condition. Electronic scanning and computer aided
manufacture were used more frequently among respon-
dents in Australia compared to the UK and New Zealand.
Semi flexible rearfoot posting materials (e.g. high dens-
ity EVA) were most frequently specified for customised
FOs for both disease stages in the UK and Australia in
our study, whilst cushioning (e.g. PORON®) top cover
materials were most frequently specified in all three
countries. These findings concur with published data
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relating to FO prescription habits unspecific to RA, from
over a decade ago [27], different countries [27, 28] and
professions outside of podiatry [29]. However, our study
found that rearfoot posting materials for customised
FOs differed among respondents in New Zealand
between the two disease stages. Customised FO shell
material specifications also varied according to the stage
of RA in all three countries. Results relating to shell ma-
terials among respondents in the UK and Australia were
inconsistent with previous studies investigating general
customised FO prescription habits, where respondents
were more likely to specify a polypropylene or medium
density EVA shell [27–29].
There are several limitations that need to be acknowl-
edged when considering the findings of this study. The
open invitation method of survey distribution did not
allow a denominator population of podiatrists to be
determined, therefore it was not possible to estimate a
response rate. As there are approximately 4800 regis-
tered podiatrists in Australia, 12,700 in the UK and 450
in New Zealand, the generalisability of our findings may
be limited. However, our findings are largely similar to
previous published data and the survey did elicit detailed
information about FO prescription habits for RA, lead-
ing to a compromise between the depth of information
and breadth of population covered.
Secondly, there were inconsistencies in responses from
two participants, who in an earlier stage of the survey
stated they did not treat either stage of the condition in
practice, but in the RA section, stated they did and pro-
vided detailed responses relating to their FO prescription
habits for people with RA. This data was included in the
analysis, but suggests the results should be interpreted
with this in mind.
Thirdly, although specific definitions of simple FOs,
prefabricated FOs and customised FOs were provided at
multiple points within the survey, it is possible that
some participants misunderstood, which has implica-
tions for the reliability of data relating to the type of FO
prescribed for each stage of the condition. For example,
when asked to specify the prefabricated FO brand most
frequently prescribed for each stage of the disease,
several respondents from each country gave invalid re-
sponses including descriptions of customised and simple
FOs (Additional file 3).
Additionally, as with any survey, there is a potential
for responder bias; respondents may have been those
with an interest in foot orthoses, and it cannot be estab-
lished whether the responses of those who did not
complete the survey would have differed. The study
asked respondents to identify what FO prescriptions
they most frequently specified, therefore the potential
for recall bias is always a consideration with this meth-
odology. However, the electronic survey technique
allowed for a wide breadth of clinical and geographical
coverage, and aimed to reduce the burden placed on
respondents.
Finally, the wording of surveys is difficult at the best of
times, and variations in terminology may affect a survey
conducted online across multiple countries. For ex-
ample, a term such as ‘semi rigid’ as it relates to orthotic
therapy may mean different things to different practi-
tioners. Nevertheless, we believe that we obtained a
reasonable balance by using terminology and providing
explanations that would have been understood by the ma-
jority of respondents, although this is an issue that requires
careful consideration for similar surveys in the future.
Future research is needed to explore the clinical
reasoning behind FO prescription choices. Several par-
ticipants indicated in free text additional comments at
the end of the survey that their FO prescriptions for RA
would depend on individual presentations (Additional
file 3). This included assessment findings, such as joint
range of motion, foot shape and deformity, and subject-
ive symptoms, such as the presence and location of pain.
These comments reflect previous research suggesting
that practitioners are influenced by patient history, foot
type, and the aim of treatment when prescribing FOs
[33]. Budget constraints, with regards to the clinician,
service provider and individual patient, were also identi-
fied by respondents in the current survey as factors that
affect decisions relating to FO prescriptions.
This study identified the types of prefabricated FOs
used in contemporary clinical practice for the treat-
ment of early and established RA, allowing podiatrists
and broader health service providers to compare their
practice against reported national and international
prescription habits. Given the frequency of foot com-
plaints in RA [4, 6] and the potential cost savings to
health services from using prefabricated FOs as
opposed to customised devices [24], there is a clear
indication of a need for further research into the
clinical and cost effectiveness of prefabricated FOs for
RA. The need for more definitive randomised con-
trolled trials for customised FOs in the management
of RA has also been identified in the literature [19,
20]. To date, clinical trials have often selected FOs
based on investigator preference rather than specific
properties of the device, mechanical effects, or how
widely used they are in clinical practice. Furthermore,
the choice of materials and design of customised FOs
used in RA trials has not always been reported,
potentially limiting the translation of trial findings to
clinical practice. Findings from our study can inform
future research investigating the physical properties of
specific prefabricated and customised FOs for RA,
and their clinical and cost effectiveness, ensuring
these studies are relevant to clinical practice.
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Conclusions
This study describes the most common FOs prescrip-
tions for people with RA within clinical practice in the
UK, Australia and New Zealand. Findings indicated vari-
ation across countries and between disease stages in the
types of orthoses prescribed, although the majority of
respondents in the UK, Australia and New Zealand
prescribed functional insoles for RA, in line with current
guidelines. Variation was seen in the specific brands of
prefabricated FOs prescribed, and in the manufacturing
methods and materials used when prescribing custo-
mised FOs. There is currently a lack of evidence to in-
form prescription choices and this should be addressed
through future research. The results allow podiatrists
and broader health service providers to compare their
practice against reported national and international
patterns, and inform future research investigating the
effectiveness of specific prefabricated and customised
FOs for people with RA.
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